Skip to main content


Cardiovascular Drugs and Therapy

Cardiovascular Drugs and Therapy OnlineFirst articles


Angiotensin II Type 1 Receptor Antagonist Azilsartan Restores Vascular Reactivity Through a Perivascular Adipose Tissue-Independent Mechanism in Rats with Metabolic Syndrome

Metabolic syndrome (MetS) facilitates the development of cardiovascular disease due to atherosclerosis. The symptoms of MetS, a chronic condition, worsen with age. Thus, MetS requires a long-term clinical treatment strategy. Angiotensin II type 1 …


Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population

Heart failure (HF) is a common and serious condition in patients with type 2 diabetes mellitus (T2DM), as well as the leading cause of hospital admission [ 1 ]. Patients with T2DM are 2.5 times more likely to develop HF than the general population …

15.08.2019 | REVIEW ARTICLE

Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon

Successful reperfusion of an infarct-related coronary artery by primary percutaneous intervention or fibrinolysis during acute ST-elevation myocardial infarction (STEMI) does not always restore myocardial tissue perfusion, a phenomenon termed …


Response Letter to Letter by Venu Jonnalagadda

Our thanks for Mr. Venu Gopal Jonnalagadda’s comments. We agree that hypertension, dyslipidemias, and diabetes mellitus (DM) are major risk factors for cardiovascular diseases (CVD). Statins are often preferred in dyslipidemias for CVD prevention …

02.08.2019 | ORIGINAL ARTICLE Open Access

The Associations of Diuretics and Laxatives Use with Cardiovascular Mortality. An Individual Patient-Data Meta-analysis of Two Large Cohort Studies

Over-the-counter (OTC) drugs are medications that can be bought without a prescription, which consequently often happens without a physician’s advice or knowledge. Especially older individuals use OTC drugs frequently [ 1 , 2 ]. In the USA …

Aktuelle Ausgaben

Über diese Zeitschrift

Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field.

Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients.

Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.

Five Reasons to Publish Your Article in Cardiovascular Drugs and Therapy:

· High usage: Articles frequently downloaded from month to month

· Wide distribution: Institutions worldwide having full text access

· Efficient handling: 18 days between submission and first decision

· Fast publication: 17 days between acceptance and online publication

· International readership: North America, Asia, Europe, Middle East and South America

Weitere Informationen

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.